Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD, Cardiovascular Cell Therapy ResearchNetwork (2011) JAMA 306: 2110-9 Current prognosis of ischemic mitral regurgitation. Implications for future management. Hickey MS, Smith LR, Muhlbaier LH, Harrell FE, Reves JG, Hinohara T, Califf RM, Pryor DB, Rankin JS (1988) Circulation 78: I51-9 Changes in cross-sectional area of the coronary lumen in the six months after angioplasty: a quantitative analysis of the variable response to percutaneous transluminal angioplasty. Johnson MR, Brayden GP, Ericksen EE, Collins SM, Skorton DJ, Harrison DG, Marcus ML, White CW (1986) Circulation 73: 467-75 Randomized trials of coronary artery bypass surgery: impact on clinical practice at Duke University Medical Center. Califf RM, Hlatky MA, Mark DB, Lee KL, Harrell FE, Rosati RA, Pryor DB (1985) Circulation 72: V136-44 ST-segment-elevation myocardial infarction treatment and the seductive lure of observational analyses. Muñoz D, Granger CB (2011) Circulation 124: 2477-9 Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Mark DB, Nelson CL, Califf RM, Harrell FE, Lee KL, Jones RH, Fortin DF, Stack RS, Glower DD, Smith LR (1994) Circulation 89: 2015-25 Single versus multiple internal mammary artery grafting for coronary artery bypass: 15-year follow-up of a clinical practice trial. Burfeind WR, Glower DD, Wechsler AS, Tuttle RH, Shaw LK, Harrell FE, Rankin JS (2004) Circulation 110: II27-35 Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. Yang EH, Gumina RJ, Lennon RJ, Holmes DR, Rihal CS, Singh M (2005) J Am Coll Cardiol 46: 2004-9 Vascular access blood flow monitoring reduces access morbidity and costs. McCarley P, Wingard RL, Shyr Y, Pettus W, Hakim RM, Ikizler TA (2001) Kidney Int 60: 1164-72 Clopidogrel: a case for indication-specific pharmacogenetics. Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR (2012) Clin Pharmacol Ther 91: 774-6 Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR, Clinical Pharmacogenetics Implementation Consortium (2011) Clin Pharmacol Ther 90: 328-32 Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention. Gumina RJ, Yang EH, Sandhu GS, Prasad A, Bresnahan JF, Lennon RJ, Rihal CS, Holmes DR, Singh M (2008) Mayo Clin Proc 83: 995-1001 Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among end-stage renal disease patients. Merkin SS, Cavanaugh K, Longenecker JC, Fink NE, Levey AS, Powe NR (2007) J Clin Epidemiol 60: 634-42 Access survival amongst hemodialysis patients referred for preventive angiography and percutaneous transluminal angioplasty. Chan KE, Pflederer TA, Steele DJ, Lilly MP, Ikizler TA, Maddux FW, Hakim RM (2011) Clin J Am Soc Nephrol 6: 2669-80 Hospital outcomes in major teaching, minor teaching, and nonteaching hospitals in New York state. Polanczyk CA, Lane A, Coburn M, Philbin EF, Dec GW, DiSalvo TG (2002) Am J Med 112: 255-61 Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Traverse JH, Henry TD, Vaughan DE, Vaughn DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN) (2009) Am Heart J 158: 356-63 Underuse of invasive procedures among Medicaid patients with acute myocardial infarction. Philbin EF, McCullough PA, DiSalvo TG, Dec GW, Jenkins PL, Weaver WD (2001) Am J Public Health 91: 1082-8 Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, Borecki IB (2013) Atherosclerosis 227: 420-4 Measuring the therapeutic efficacy of coronary revascularization: Implications for future management. Rankin JS, Harrell FE (2006) J Thorac Cardiovasc Surg 131: 944-8 Epidural removal after perioperative myocardial infarction and coronary stent placement. Hackney CW, Wilson SH, Abernathy JH, McEvoy MD (2014) Reg Anesth Pain Med 39: 252 Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. Miller JM, Smalling R, Ohman EM, Bode C, Betriu A, Kleiman NS, Schildcrout JS, Bastos E, Topol EJ, Califf RM (1999) Am J Cardiol 84: 779-84 Natural history of patients with single-vessel disease suitable for percutaneous transluminal coronary angioplasty. Hlatky MA, Califf RM, Kong Y, Harrell FE, Rosati RA (1983) Am J Cardiol 52: 225-9 New trials and therapies for acute myocardial infarction. Gumina RJ (2007) Med Clin North Am 91: 729-49; xii Progression of nonculprit plaque stenosis following successful percutaneous intervention. Bunch TJ, Rihal CS, Gumina RJ, Cooper L, Caplice NM (2008) Angiology 59: 236-9 Using quality improvement methods to improve door-to-balloon time at an academic medical center. Huang RL, Donelli A, Byrd J, Mickiewicz MA, Slovis C, Roumie C, Elasy TA, Dittus RS, Speroff T, Disalvo T, Zhao D (2008) J Invasive Cardiol 20: 46-52 When to call it a day: incremental risk of amputation and death after multiple revascularization. Hawkins AT, Schaumeier MJ, Smith AD, Hevelone ND, Nguyen LL (2014) Ann Vasc Surg 28: 35-47 LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD, Cardiovascular Cell Therapy Research Network (2010) Tex Heart Inst J 37: 412-20
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.